BioCentury | Oct 6, 2014
Finance

Winner takes Alios

Antiviral developer Alios BioPharma Inc. raised strategic investments from three pharmas, but they all lost out to Johnson & Johnson (NYSE:JNJ). With a $1.7 billion bid on Sept. 30, J&J netted a candidate in Phase...
BioCentury | Oct 6, 2014
Company News

Alios, J&J deal

Johnson & Johnson is acquiring Alios for about $1.8 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV) infection. In July, the oral nucleoside analog met the...
BioCentury | Oct 1, 2014
Top Story

J&J buying Alios for $1.75B

Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus (RSV). In July, the...
Items per page:
1 - 3 of 3